Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-665-9 | CAS number: 67-71-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Effects on fertility
Description of key information
Reproductive toxicity study
Based on the data available from given study .NOAEL for test material was considered to be 1000mg/kg /day for reproductive toxicity, when male and female rats were treated with test material orally. Thus, comparing this value with the criteria of CLP regulation test material is not likely to classify as reproductive toxicant.
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Justification for type of information:
- Data is from peer-reviewed journal.
- Qualifier:
- according to guideline
- Guideline:
- other: US Food and Drug Administration principles (FDA, 1982) and Organization for Economic Co-operation and Development (OECD) guidelines for developmental toxicity (No. 414) (OECD, 2006).
- Principles of method if other than guideline:
- The present study was undertaken to determine the reproductive toxicity potential of test chemical.when administered orally to rats during the period of major organogenesis and histogenesis.
- GLP compliance:
- not specified
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source of test material: Cardinal Nutrition, Inc. (Vancouver, WA).
- Expiration date of the lot/batch: No data
- Purity: 99.9%
RADIOLABELLING INFORMATION (Not applicable)
- Radiochemical purity: N/A
- Specific activity: N/A
- Locations of the label: N/A
- Expiration date of radiochemical substance: N/A
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: stored at room temperature.
- Stability under test conditions: the formulations were stable for 32 days for concentrations ranging from 10 to 100 mg/ml when stored at room temperature.
- Solubility and stability of the test substance in the solvent/vehicle: No data
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: No data
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: No data
- Preliminary purification step (if any): No data
- Final dilution of a dissolved solid, stock liquid or gel: No data
- Final preparation of a solid: No data
FORM AS APPLIED IN THE TEST (if different from that of starting material): No data
OTHER SPECIFICS: No data - Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Taconic Farms, Germantown, NY
- Females (if applicable) nulliparous and non-pregnant: [yes]
- Age at study initiation: 7 to 9 weeks
- Weight at study initiation: between 145 and 215 g/rat
- Fasting period before study: No data available
- Housing: Quarantine in plastic cages
- Use of restrainers for preventing ingestion (if dermal): no
- Diet (e.g. ad libitum): Harlan Teklad Certified Rodent Diet #8728C, ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 4 degC
- Humidity (%): No data available
- Air changes (per hr): No data available
- Photoperiod (hrs dark / hrs light): 12-h light/dark cycle
IN-LIFE DATES: From: To: No data available - Route of administration:
- oral: gavage
- Type of inhalation exposure (if applicable):
- not specified
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: Formulations were prepared in deionized water at 10, 100, and 200 mg/ml concentrations for the 50, 500, and 1000 mg/kg dose levels, respectively.
DIET PREPARATION
- Rate of preparation of diet (frequency):No data
- Mixing appropriate amounts with (Type of food): No data
- Storage temperature of food: No data
VEHICLE
- Justification for use and choice of vehicle (if other than water): No data
- Concentration in vehicle: 50, 500,1000 mg/kg
- Amount of vehicle (if gavage): 5 ml/kg
- Lot/batch no. (if required): No data
- Purity: No data - Details on mating procedure:
- - M/F ratio per cage: 1:1 mating scheme (i.e., one male:one female)
- Length of cohabitation: overnight
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy
- After ... days of unsuccessful pairing replacement of first male by another male with proven fertility. No data available
- Further matings after two unsuccessful attempts: no
- After successful mating each pregnant female was caged (how): males were removed and females were individually housed for the rest of the experiment.
- Any other deviations from standard protocol: To facilitate the teratogenic evaluation of pups, a staggered-start design (via staggered mating) was employed. Mating was staggered over six days resulting in six series. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Aliquots of the formulations were transferred to dosing vials and samples representing each dose level from the first preparation were analyzed by gas chromatography. The purity of test chemical was 99.9%.
- Duration of treatment / exposure:
- 14 days (on gestation days 6–20)
Total exposure period: 20 days - Frequency of treatment:
- Daily
- Details on study schedule:
- Terminal killing: 21st day of gestation
- Dose / conc.:
- 0 other: mg/kg
- Remarks:
- vehicle group
- Dose / conc.:
- 50 other: mg/kg
- Dose / conc.:
- 500 other: mg/kg
- Dose / conc.:
- 1 000 other: mg/kg
- No. of animals per sex per dose:
- Total: 98
0 mg/kg/day : 25 timed-bred primiparous dams
50 mg/kg/day : 24 timed-bred primiparous dams
500 mg/kg/day : 25 timed-bred primiparous dams
1000 mg/kg/day : 24 timed-bred primiparous dams - Control animals:
- yes
- Details on study design:
- No data available
- Positive control:
- No data available
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: No data
- Time schedule:
- Cage side observations checked in table [No.?] were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule:
BODY WEIGHT: Yes
- Time schedule for examinations: Body weights were recorded on gestation days 0 (sperm-positive day/randomization), 3, 6, 9, 12, 15, 18, and 21.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes
- Feed consumption was calculated for each period between weighings.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data
- Time schedule for examinations:
- Oestrous cyclicity (parental animals):
- No data available
- Sperm parameters (parental animals):
- No data available
- Litter observations:
- No data available
- Postmortem examinations (parental animals):
- SACRIFICE
All dams were euthanized using CO2 asphyxiation on their 21st day of gestation and underwent a cesarean section.
GROSS NECROPSY
Gross necropsy consisted of examination of the brain and all organs in the thoracic and abdominal cavities of the dams.
Pregnancy status, number of corpora lutea was examined.
The uterus and ovaries were weighed. - Postmortem examinations (offspring):
- GROSS NECROPSY
- Gross necropsy consisted of external morphological and internal examinations including the cervical, thoracic, and abdominal viscera.
- Statistics:
- Dam weights, litter body weights, and viability data were analyzed by a two-way analysis of variance (ANOVA). In the presence of a significant main effect, all post-hoc comparisons were performed using Dunnett’s test (two-tail). Gross, visceral, cephalic, and skeletal data were analyzed by Chi-Square/Fisher’s Exact tests (fetal N) when incidence in the treated rats was higher (i.e., when the difference in the absolute number of fetuses affected is greater than three) than controls. A minimum statistical significance level of p ≤ 0.05 was used in all cases.
- Reproductive indices:
- No data available
- Offspring viability indices:
- No data available
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No clinical signs of toxicity were observed.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- not specified
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Body weight was similar among all groups.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Feed consumption was not affected.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- No histopathological lesions in organ and tissues were observed.
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Reproductive function: oestrous cycle:
- not specified
- Reproductive function: sperm measures:
- not specified
- Reproductive performance:
- effects observed, treatment-related
- Description (incidence and severity):
- No evidence of maternal toxicity was observed.
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- clinical signs
- body weight and weight gain
- food consumption and compound intake
- organ weights and organ / body weight ratios
- gross pathology
- histopathology: non-neoplastic
- reproductive performance
- Remarks on result:
- other: No evidence of maternal toxicity was observed.
- Critical effects observed:
- not specified
- System:
- other: not specified
- Organ:
- not specified
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No clinical signs were observed.
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Sexual maturation:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Oral administration of test chemical to pregnant rats at doses of 50, 500, or 1000 mg/kg/day did not result in any structural malformations or fetal anomalies as evaluated by gross external, cephalic, visceral and skeletal examinations.
- Histopathological findings:
- not specified
- Other effects:
- not specified
- Behaviour (functional findings):
- not specified
- Developmental immunotoxicity:
- not specified
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 1 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- viability
- clinical signs
- mortality
- body weight and weight gain
- gross pathology
- other: Fetotoxicity
- Remarks on result:
- other: No evidence of embryo-fetal toxicity was observed.
- Critical effects observed:
- not specified
- System:
- other: not specified
- Organ:
- not specified
- Reproductive effects observed:
- not specified
- Treatment related:
- not specified
- Conclusions:
- Under the conditions of this study, the no-observed-adverse-effect level (NOAEL) for maternal and developmental toxicity was considered to be 1000 mg/kg/day.When female rats were treated with test chemical orally.
- Executive summary:
The objective of the study was to determine the reproductive toxicity potential of test chemical when administered orally to pregnant rats during the period of major organogenesis and histogenesis. In a preliminary dose-finding study, distilled microprill (i.e., microspherical pellets of test chemical ) was administered by oral gavage at dose levels of 0 (vehicle control), 50, 250, 500, and 1000 mg/kg/day to 8–9 sperm-positive female Sprague–Dawley rats/group/day on gestation days 6–20. No evidence of maternal or fetal toxicity was observed. For the definitive study, four groups of 24–25 timedbred primiparous female rats were administered 0, 50, 500, or 1000 mg /kg/day via gavage on gestation days 6–20. Maternal feed consumption, body weight, body weight gain, uterus weight and corrected body weight/body weight gain were unaffected by treatment. No evidence of maternal toxicity, and no significant differences in litter viability, litter size, or litter body weight were detected. Fetal evaluations failed to show any biologically significant increase in the incidence of anomalies in the treated groups, and no malformations were seen in any of the fetuses. No evidence of fetal mortality, alterations to growth, or structural alterations were observed in the fetuses of dams administered 50–1000 mg/kg/day. Therefore, under the conditions of this study, the no-observed-adverse-effect level (NOAEL) for maternal and developmental toxicity was considered to be 1000 mg/kg/day.When female rats were treated with test chemical orally.
Reference
Embryo-fetal toxicity summary
No evidence of embryo or fetal toxicity, or treatment related alterations in fetal body weights or fetal examinations (gross external, visceral, cephalic, or skeletal) was observed in this study at doses up to 1000 mg/kg .
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Data is Klimicsh 2 and from authoritative database
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Reproductive toxicity study
Data available from given study was reviewed to determine the reproductive toxicity of test chemical.The study as mentioned below:
The objective of the study was to determine the reproductive toxicity potential of test chemical when administered orally to pregnant rats during the period of major organogenesis and histogenesis. In a preliminary dose-finding study, distilled microprill (i.e., microspherical pellets of test chemical ) was administered by oral gavage at dose levels of 0 (vehicle control), 50, 250, 500, and 1000 mg/kg/day to 8–9 sperm-positive female Sprague–Dawley rats/group/day on gestation days 6–20. No evidence of maternal or fetal toxicity was observed. For the definitive study, four groups of 24–25 timedbred primiparous female rats were administered 0, 50, 500, or 1000 mg /kg/day via gavage on gestation days 6–20. Maternal feed consumption, body weight, body weight gain, uterus weight and corrected body weight/body weight gain were unaffected by treatment. No evidence of maternal toxicity, and no significant differences in litter viability, litter size, or litter body weight were detected. Fetal evaluations failed to show any biologically significant increase in the incidence of anomalies in the treated groups, and no malformations were seen in any of the fetuses. No evidence of fetal mortality, alterations to growth, or structural alterations were observed in the fetuses of dams administered 50–1000 mg/kg/day. Therefore, under the conditions of this study, the no-observed-adverse-effect level (NOAEL) for maternal and developmental toxicity was considered to be 1000 mg/kg/day.When female rats were treated with test chemical orally.
NOAEL for test material was considered to be 1000mg/kg /day for reproductive toxicity, when male and female rats were treated with test material orally. Thus, comparing this value with the criteria of CLP regulation test material is not likely to classify as reproductive toxicant.
Effects on developmental toxicity
Description of key information
Developmental toxicity study
Based on the given study available for the test chemical was reviewed to determine the developmental toxicity, NOAELfor test chemical was considered to be 1000 mg /kg bw/day .When rats were treated with test chemical orally. Thus, comparing this value with the criteria of CLP regulation test chemical is not likely to classify as reproductive and developmental toxicant.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Justification for type of information:
- Data is from peer-reviewed journal
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Principles of method if other than guideline:
- The objective of the study was to determine the developmental toxicity potential of test chemical when administered orally to pregnant rats during the period of major organogenesis and histogenesis.
- GLP compliance:
- not specified
- Limit test:
- yes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source of test material: Cardinal Nutrition, Inc. (Vancouver, WA).
- Expiration date of the lot/batch: No data
- Purity: 99.9%
RADIOLABELLING INFORMATION (Not applicable)
- Radiochemical purity: N/A
- Specific activity: N/A
- Locations of the label: N/A
- Expiration date of radiochemical substance: N/A
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: stored at room temperature.
- Stability under test conditions: the formulations were stable for 32 days for concentrations ranging from 10 to 100 mg/ml when stored at room temperature.
- Solubility and stability of the test substance in the solvent/vehicle: No data
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: No data
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: No data
- Preliminary purification step (if any): No data
- Final dilution of a dissolved solid, stock liquid or gel: No data
- Final preparation of a solid: No data
FORM AS APPLIED IN THE TEST (if different from that of starting material): No data
OTHER SPECIFICS: No data - Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Taconic Farms, Germantown, NY
- Females (if applicable) nulliparous and non-pregnant: [yes]
- Age at study initiation: 7 to 9 weeks
- Weight at study initiation: between 145 and 215 g/rat
- Fasting period before study: No data available
- Housing: Quarantine in plastic cages
- Use of restrainers for preventing ingestion (if dermal): no
- Diet (e.g. ad libitum): Harlan Teklad Certified Rodent Diet #8728C, ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: Two weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 4 degC
- Humidity (%): No data available
- Air changes (per hr): No data available
- Photoperiod (hrs dark / hrs light): 12-h light/dark cycle
IN-LIFE DATES: From: To: No data available - Route of administration:
- oral: gavage
- Type of inhalation exposure (if applicable):
- not specified
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: Formulations were prepared in deionized water at 10, 100, and 200 mg/ml concentrations for the 50, 500, and 1000 mg/kg dose levels, respectively.
DIET PREPARATION
- Rate of preparation of diet (frequency): No data
- Mixing appropriate amounts with (Type of food): No data
- Storage temperature of food: No data
VEHICLE
- Justification for use and choice of vehicle (if other than water): No data
- Concentration in vehicle: 50, 500,1000 mg/kg
- Amount of vehicle (if gavage): 5 ml/kg
- Lot/batch no. (if required): No data
- Purity: No data - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Aliquots of the formulations were transferred to dosing vials and samples representing each dose level from the first preparation were analyzed by gas chromatography. The purity of MSM was 99.9%.
- Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused:
- M/F ratio per cage: 1:1 mating scheme (i.e., one male:one female)
- Length of cohabitation: overnight
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy
- After ... days of unsuccessful pairing replacement of first male by another male with proven fertility. No data available
- Further matings after two unsuccessful attempts: no
- Verification of same strain and source of both sexes: no
- Any other deviations from standard protocol: To facilitate the teratogenic evaluation of pups, a staggered-start design (via staggered mating) was employed. Mating was staggered over six days resulting in six series. - Duration of treatment / exposure:
- 14 days (on gestation days 6–20)
Total exposure period: 20 days. - Frequency of treatment:
- Daily
- Duration of test:
- Terminal killing: 21st day of gestation
- Dose / conc.:
- 0 other: mg/kg
- Remarks:
- Vehicle group
- Dose / conc.:
- 50 other: mg/kg
- Dose / conc.:
- 500 other: mg/kg
- Dose / conc.:
- 1 000 other: mg/kg
- No. of animals per sex per dose:
- Total: 98
0 mg/kg/day : 25 timed-bred primiparous dams
50 mg/kg/day : 24 timed-bred primiparous dams
500 mg/kg/day : 25 timed-bred primiparous dams
1000 mg/kg/day : 24 timed-bred primiparous dams - Control animals:
- yes
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: No data
- Time schedule:
- Cage side observations checked in table [No.?] were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule:
BODY WEIGHT: Yes
- Time schedule for examinations: Body weights were recorded on gestation days 0 (sperm-positive day/randomization), 3, 6, 9, 12, 15, 18, and 21.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes
- Feed consumption was calculated for each period between weighings.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data
- Time schedule for examinations:
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 21
- Organs examined: Gross necropsy consisted of examination of the brain and all organs in the thoracic and abdominal cavities of the dams.
- Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Fetal examinations:
- - External examinations: Yes
- Soft tissue examinations: Yes
- Skeletal examinations: Yes
- Head examinations: Yes - Statistics:
- Dam weights, litter body weights, and viability data were analyzed by a two-way analysis of variance (ANOVA). In the presence of a significan t main effect, all post-hoc comparisons were performed using Dunnett’s test (two-tail). Gross, visceral, cephalic, and skeletal data were analyzed by Chi-Square/Fisher’s Exact tests (fetal N) when incidence in the treated rats was higher (i.e., when the difference in the absolute number of fetuses affected is greater than three) than controls. A minimum statistical significance level of p ≤ 0.05 was used in all cases.
- Indices:
- No data
- Historical control data:
- No data
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No clinical signs of toxicity were observed.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- not specified
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Body weight was similar among all groups.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Feed consumption was not affected.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- Uterine weights were similar across all groups.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No gross external anomalies were observed.
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- No histopathological lesions in organ and tissues were observed.
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Details on results:
- No evidence of maternal toxicity by test chemical was observed in this study.
- Number of abortions:
- not specified
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- not specified
- Changes in number of pregnant:
- not specified
- Other effects:
- not specified
- Details on maternal toxic effects:
- No evidence of maternal toxicity was observed. No effects observed on maternal body weight, uterus weight, body weight gain. No clinical signs of toxicity were observed.
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- clinical signs
- dead fetuses
- early or late resorptions
- food consumption and compound intake
- gross pathology
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
- pre and post implantation loss
- total litter losses by resorption
- Remarks on result:
- other: No evidence of maternal toxicity was observed.
- Abnormalities:
- no effects observed
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- No significant differences in male, female or combined fetal weights were detected.
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- not specified
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- not specified
- External malformations:
- no effects observed
- Description (incidence and severity):
- No gross external anomalies were observed; all fetuses appeared normal and none were malformed.
- Skeletal malformations:
- no effects observed
- Description (incidence and severity):
- No treatment-related skeletal anomalies were seen in the low, mid or high dose groups.
- Visceral malformations:
- no effects observed
- Description (incidence and severity):
- No visceral malformations were observed in any of the fetuses examined.
- Other effects:
- no effects observed
- Details on embryotoxic / teratogenic effects:
- No evidence of embryo or fetal toxicity, or treatment related alterations in fetal body weights or fetal examinations (gross external, visceral, cephalic, or skeletal) was observed in this study upto 1000 mg/kg
No significant differences in litter viability, litter size, or litter body weight were detected. - Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- reduction in number of live offspring
- fetal/pup body weight changes
- changes in litter size and weights
- external malformations
- skeletal malformations
- visceral malformations
- Remarks on result:
- other: No evidence of embryo or fetal toxicity was observed.
- Abnormalities:
- no effects observed
- Developmental effects observed:
- not specified
- Treatment related:
- not specified
- Conclusions:
- Under the conditions of this study, the no-observed-adverse-effect level (NOAEL) for maternal and developmental toxicity was considered to be 1000 mg/kg/day.
- Executive summary:
The objective of the study was to determine the developmental toxicity potential of test chemical when administered orally to pregnant rats during the period of major organogenesis and histogenesis. In a preliminary dose-finding study, distilled microprill (i.e., microspherical pellets of test chemical) was administered by oral gavage at dose levels of 0 (vehicle control), 50, 250, 500, and 1000 mg/kg/day to 8–9 sperm-positive female Sprague–Dawley rats/group/day on gestation days 6–20. No evidence of maternal or fetal toxicity was observed. For the definitive developmental study, four groups of 24–25 timed bred primiparous female rats were administered 0, 50, 500, or 1000 mg/kg/day via gavage on gestation days 6–20. Maternal feed consumption, body weight, body weight gain, uterus weight and corrected body weight/body weight gain were unaffected by treatment. No evidence of maternal toxicity, and no significant differences in litter viability, litter size, or litter body weight were detected. Fetal evaluations failed to show any biologically significant increase in the incidence of anomalies in the treated groups, and no malformations were seen in any of the fetuses. No evidence of fetal mortality, alterations to growth, or structural alterations were observed in the fetuses of dams administered 50–1000 mg/kg/day. Therefore, under the conditions of this study, the no-observed-adverse-effect level (NOAEL) for maternal and developmental toxicity was considered to be 1000 mg/kg/day.
Reference
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Data is Klimicsh 2 and from authoritative database
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Developmental toxicity study
Data available from given study for test chemicals was reviewed to determine the developmental toxicity of test chemical. The studies are as mentioned below:
The objective of the study was to determine the reproductive toxicity potential of test chemical when administered orally to pregnant rats during the period of major organogenesis and histogenesis. In a preliminary dose-finding study, distilled microprill (i.e., microspherical pellets of test chemical ) was administered by oral gavage at dose levels of 0 (vehicle control), 50, 250, 500, and 1000 mg/kg/day to 8–9 sperm-positive female Sprague–Dawley rats/group/day on gestation days 6–20. No evidence of maternal or fetal toxicity was observed. For the definitive study, four groups of 24–25 timedbred primiparous female rats were administered 0, 50, 500, or 1000 mg /kg/day via gavage on gestation days 6–20. Maternal feed consumption, body weight, body weight gain, uterus weight and corrected body weight/body weight gain were unaffected by treatment. No evidence of maternal toxicity, and no significant differences in litter viability, litter size, or litter body weight were detected. Fetal evaluations failed to show any biologically significant increase in the incidence of anomalies in the treated groups, and no malformations were seen in any of the fetuses. No evidence of fetal mortality, alterations to growth, or structural alterations were observed in the fetuses of dams administered 50–1000 mg/kg/day. Therefore, under the conditions of this study, the no-observed-adverse-effect level (NOAEL) for maternal and developmental toxicity was considered to be 1000 mg/kg/day.When female rats were treated with test chemical orally.
Based on the given study available for the test chemical were reviewed to determine the developmental toxicity, NOAELfor test chemical was considered to be 1000 mg /kg bw/day .When rats were treated with test chemical orally. Thus, comparing this value with the criteria ofCLP regulation testchemical isnot likelyto classify as reproductive and developmental toxicant.
Justification for classification or non-classification
Thus, comparing this value with the criteria ofCLP regulation testchemical isnot likelyto classify as reproductive and developmental toxicant.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.